Vor Biopharma has pivoted from oncology to autoimmune disease, licensing global rights for telitacicept—a fusion protein targeting BAFF and APRIL cytokines—approved in China and in Phase 3 development for generalized myasthenia gravis. The company also appointed Jean-Paul Kress as CEO and raised $175 million via a PIPE financing. This strategic shift follows clinical headwinds with previous cancer programs and marks a renewed focus on systemic autoimmune disorders, leveraging validated targets from innovative Chinese biotech firms.